| Name | Title | Contact Details |
|---|
Pharmacy Access Solutions Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Central Peninsula Hospital, Inc., an acute care hospital, provides patient and resident centered care services serving the Central Peninsula area. It offers emergency care, anesthesia, emergency medicine, family medicine, ENT, general surgery, internal medicine, neurology, OB/GYN, ophthalmology, orthopedics, pathology, pediatrics, podiatry, psychiatry, and radiology services; and behavioral health services that include depression screenings, substance abuse treatment, and substance abuse treatment services. The company also provides imaging services that include diagnostic imaging, digital mammography examinations, computer axial tomography procedures, ultrasound/sonography, nuclear medicine, and magnetic resonance imaging; physical, occupational, speech, and massage therapy services; outpatient weight loss, walking and exercise programs, cardiac rehabilitation, and diabetes management services; and diabetes education services. In addition, it offers family birth center services; laboratory services that include chemistry, hematology, transfusion medicine, serology, urinalysis, microbiology, and molecular biology testing; various treatments to outpatients include chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement; and sleep center services. Central Peninsula Hospital, Inc. was formerly known as Central Peninsula General Hospital, Inc. The company was founded in 1971 and is based in Soldotna, Alaska with practices in Kenai and Soldotna, Alaska.
CFHP was established in 1995, by the University Health System, specifically to begin providing health care coverage to the citizens of Bexar and the surrounding seven counties. As the only locally owned and managed, non-profit health plan in the area,
Retractable Technologies, Inc. is a Little Elm, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.